NUVENDRA®lorvanimab-nvdr injection
Clearer skin, sooner
The safest biologic choice for your patientsA biologic option for adults with plaque psoriasis
Indicated for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
- 74% reached PASI 75 at Week 16 vs 52% with RAXIFLO (primary endpoint; p<0.001)1,2
- Superior clearance versus RAXIFLO across every patient type studied2Superior PASI 75 versus RAXIFLO in the overall study population2
PASI 75 at Week 16
80%60%40%
100%50%0%
74%52%
NUVENDRARAXIFLO
Inflammatory bowel disease; hypersensitivity reactions, including anaphylaxis. See full Prescribing Information.
Sample artwork